Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DZ-002 in advanced solid tumors
NCT04970992Phase 1Completed
- Sponsor
- Da Zen Theranostics
- Start
- Aug 2021
- Primary completion
- Nov 2024
- Modality
- Antibody-Drug Conjugates (ADCs), Peptide-Drug Conjugates
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of DZ-002 in solid tumor, lymphoma, prostate cancer (PCa) and 1 more, sponsored by Da Zen Theranostics. Primary endpoints: Incidence and severity of treatment emergent adverse events at 24 months and Maximum Tolerated Dose at 24 months. Started Aug 2021; status: completed.
02
Drugs
DZ-002
03
Conditions
solid tumorlymphomaprostate cancer (PCa)pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT04970992.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04970992.